Selinexor in Combination With Irinotecan in Adenocarcinoma of Stomach and Distal Esophagus

NCT02283359 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

3

Enrollment

OTHER

Sponsor class

Stopped Principal Investigator left the institution

Conditions

Esophageal Cancer
Gastric Cancer

Interventions

DRUG: Selinexor
DRUG: Irinotecan

Sponsor

H. Lee Moffitt Cancer Center and Research Institute